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Abstract
Background: Polybrominated diphenyl ethers (PBDEs) have been widely used as flame retardants in consumer 
products. PBDEs may affect thyroid hormone homeostasis, which can result in irreversible damage of cognitive 
performance, motor skills and altered behaviour. Thus, in utero exposure is of very high concern due to critical 
windows in fetal development.
Methods: A human ex vivo placenta perfusion system was used to study the kinetics and extent of the placental 
transfer of BDE-47, BDE-99 and BDE-209 during four-hour perfusions. The PBDEs were added to the maternal 
circulation and monitored in the maternal and fetal compartments. In addition, the perfused cotyledon, the 
surrounding placental tissue as well as pre-perfusion placental tissue and umbilical cord plasma were also analysed. 
The PBDE analysis included Soxhlet extraction, clean-up by adsorption chromatography and GC-MS analysis.
Results and Discussion: Placental transfer of BDE-47 was faster and more extensive than for BDE-99. The fetal-
maternal ratios (FM-ratio) after four hours of perfusion were 0.47 and 0.25 for BDE-47 and BDE-99, respectively, while 
the indicative permeability coefficient (IPC) measured after 60 minutes of perfusion was 0.26 h-1 and 0.10 h-1, 
respectively. The transport of BDE-209 seemed to be limited. These differences between the congeners may be related 
to the degree of bromination. Significant accumulation was observed for all congeners in the perfused cotyledon as 
well as in the surrounding placental tissue.
Conclusion: The transport of BDE-47 and BDE-99 indicates in utero exposure to these congeners. Although the 
transport of BDE-209 was limited, however, possible metabolic debromination may lead to products which are both 
more toxic and transportable. Our study demonstrates fetal exposure to PBDEs, which should be included in risk 
assessment of PBDE exposure of women of child-bearing age.
Background
Polybrominated diphenyl ethers (PBDEs) have been
widely used as flame retardant additives in a variety of
products of everyday use, e.g. electric equipment, textiles
and furniture upholstery. As they are not chemically
bound to the polymers, they can be emitted during the
product's life cycle and accumulate in the environment.
With logKow values of 6-7 (for tetra and penta-BDEs),
they accumulate in lipid-rich tissue and biomagnify in the
food chain [1]. The congeners BDE-47 and BDE-99 are
among the most prevalent in the environment [1], even
though their production and use was banned in large
parts of the world, including the EU in 2004 [2]. Due to
their persistency and toxicity, the tetra- to hepta-BDEs
have also been added to Annex A of the Stockholm Con-
vention, which aims to protect human health and the
environment by eliminating toxic persistent organic pol-
lutants (POPs) [3]. However, exposure to these com-
pounds is likely to continue, due to the use of existing
PBDE-containing products and the occurrence of BDE-
47 and BDE-99 in the environment. The fully brominated
congener, BDE-209, has different chemical properties
than BDE-47 and BDE-99 and is less persistent in the
environment despite its extreme hydrophobicity (logKow
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≥ 10) [1]. The debromination of BDE-209 can occur by
photolysis to form octa- and nonaBDEs as initial degra-
dation products [4,5]. Furthermore, biotransformation of
BDE-209 in fish and rodents results in lower brominated
congeners, for example hexaBDEs [6,7] with further
debromination possible. Generally, the lower brominated
congeners are more toxic and bioaccumulative than BDE-
209 [8,9]. In spite of its apparently lower persistence,
BDE-209 has been found at very high concentrations in
indoor environments, e.g., dust [10,11], as well as in
humans and wildlife [12,13]. Few restrictions have been
placed on the use of BDE-209, but since June 2008 the use
of BDE-209 in electronic products has been banned in
the EU [2]. The two US producers of BDE-209 and the
largest US importer recently announced to phase out
BDE-209 by the end of 2013 [14].
While PBDEs are beneficial for fire safety and save lives,
they are also endocrine disrupters that interfere with thy-
roid hormone homeostasis [15]. The thyroid hormones
are particularly important for normal brain development
and impairment can result in irreversible deficits in cog-
nitive performance and motor skills as well as altered
behaviour [16,17]. In animal studies, PBDEs have been
found to alter the levels of thyroid hormones in offspring
after low doses of maternal exposure to PBDEs in both
rodents [18] and sheep [19]. In human studies, PBDEs in
house dust have been related to changes in hormone lev-
els in men [20] and elevated levels of PBDEs have been
found in breast milk of mothers to newborn boys with
cryptorchidism [21].
PBDEs have been found in various human tissues,
including umbilical cord blood [12,22]. The presence of
PBDEs in cord blood indicates placental passage of
PBDEs. In the present study, an ex vivo human placenta
perfusion system was applied to investigate the transfer
of the congeners BDE-47, BDE-99 and BDE-209 across
the placenta. The extent of the transfer, kinetics and accu-
mulation in the placental tissue have been compared for
the three congeners. The advantage of using the human
placenta perfusion model is the controlled environment
in which the kinetics of the transfer can be studied and
extrapolation from animals to humans is avoided.
Methods
Placenta perfusions
The study was approved by the regional Ethics Commit-
tee (KF 01-145/03 + KF(11) 260063) and the Data Protec-
tion Agency. All mothers gave informed written consent.
Term placentas (n = 37) were collected and successful
perfusions were performed on five placentas from four
vaginal births and one Caesarean section directly after
delivery. The placentas were injected with a Krebs Ringer
buffer containing heparin (5000 IU/ml, 5 ml/l medium) to
prevent any remaining blood in fetal vessels from coagu-
lating. The perfusions were performed in a dual perfusion
system as previously described [23,24]. Of the 37 placen-
tas collected 22 were suitable for cannulation (checkpoint
one in placental perfusion as described in [23]) in a chori-
onic artery vein pair within 30 minutes of delivery (one
placenta was cannulated within 58 min, Table 1). Next,
the lobule containing the perfused cotyledon was cut
from the placenta (9 cm diameter) and placed in the per-
fusion chamber. The maternal circulation was connected
by blunt cannulation of the intervillous space surround-
ing the perfused cotyledon. The perfusion media (100 mL
each in fetal and maternal reservoirs) were circulated by
peristaltic pumps and consisted of Krebs Ringer Buffer
containing heparin (5000 IU/mL, Copenhagen University
Hospital Pharmacy, 5 mL/L medium), glucose (0.6 g/100
mL), Pen-Strep (1% Substrate department standard solu-
tion, Panum Institute Copenhagen) and physiological lev-
els of Human Serum Albumin (20% solution, CSL
Behring Gmbh, dialysed in Krebs Ringer Buffer, maternal
reservoir: 30 g/L; fetal reservoir: 40 g/L) and gassed with
95% O2/5% CO2 and 95% N2/5% CO2 in the maternal and
fetal reservoirs, respectively. Of the 22 cannulated pla-
centas only five fulfilled the criteria set for further prog-
ress in the experiments. After at least 30 minutes of pre-
perfusion to stabilise temperature and oxygen content,
BDE-47, BDE-99 and BDE-209 (Cambridge Isotopes Lab-
oratories, 1 μg/mL in ethanol, 100 μL added; final con-
centration of 1 ng/mL) and the positive control substance
antipyrine dissolved in H2O (Aldrich-Chemie, Germany;
final concentration of 100 μg/mL) were added to the
maternal reservoir. The applied concentrations of PBDEs
were a compromise between achieving final levels rela-
tively close to in vivo levels and having a detection fre-
quency close to 100%. Setting the BDE-209 level was
further complicated by the extremely low water solubility
and generally higher blank levels than for the other con-
geners. The perfusions were run for four hours, and 6 mL
were sampled at t = 0 from the maternal circulation and
from both reservoirs before addition of the compounds
and at 2, 30, 60, 130, 190 and 240 minutes after addition
of the compounds. The sampled volume was not
replaced.
The pH (7.2-7.4), glucose and lactate concentrations
(glucose > 6 mM), and O2 tension in the maternal perfu-
sion medium (30-35 kPa), in the fetal perfusion medium
(10-15 kPa), and in the fetal venous outflow (15-20 kPa)
were measured every 30 minutes using an ABL5 blood
gas analyser (Radiometer, Denmark). Adjustments were
made using 1 M HCl or 1 M NaOH to adjust pH, glucose
solution (2,61 g/L) and increasing or decreasing the rate
of 95% N2/5% CO2 gassing in the fetal perfusate or 95%
O2/5% CO2 gassing in the maternal perfusate to adjust
pO2 after each measurement [23].Frederiksen et al. Environmental Health 2010, 9:32
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In addition to the perfusion samples, the three PBDE
congeners were analysed in umbilical cord blood and in
the placental tissue before and after the perfusion. Sam-
ples of umbilical cord blood were taken if possible and
processed to collect plasma. Subsamples of the placental
tissue were taken before perfusion as well as from the cot-
yledon and the surrounding tissue after perfusion. Prior
to placenta perfusions, adsorption tests had been per-
formed: The chambers and tubes were perfused without
placental tissue to investigate loss of substance during the
perfusion, for instance through adsorption to the perfu-
sion system. These tests showed that 25-35% of BDE-47
and BDE-99 could adsorb within the perfusion system,
while no loss of BDE-209 was observed.
PBDE and antipyrine analyses
The analysis of the positive control substance antipyrine
in the perfusate samples was carried out on a LaChrom
HPLC system equipped with a C-18 column and a Securi-
tyGuard precolumn eluted with methanol:water (55:45)
as previously described [25].
The analysis of the PBDEs in the perfusion medium,
plasma and placental tissue followed accredited methods
for analysis of PBDEs in biota as previously described
[13,26,27]. In brief, 5 ml of perfusate/plasma or up to 24 g
homogenised placental tissue was dried with diatoma-
ceous earth and extracted by Soxhlet using 350 mL and
500 mL hexane:acetone (4:1), respectively. The extracts
were purified by multi-layer adsorption chromatography
and reduced to 500 μL. Instrumental analysis was per-
Table 1: Perfusion variables.
Parameter\Perfusion no. 12345
Volume loss, maternal (ml/min) 0.016 0.025 n.d. 0.012 0.016
Volume loss, fetal (ml/min) 0.008 0.005 0.045a 0.003 0.025
Flow, fetal (ml/min) 3.1 3.2 3.1a 2.9 3.1
Time, birth to lab (min) n.d. 29 58 24 n.d.
P r e - p e r f u s i o n  ( m i n ) 4 84 35 64 34 8
Antipyrene, FM-ratio (at 240 min) 0.95 1.21 0.92 0.74
(1.04 at 190 min)
1.02
Maternal age (yr) 26 24 30 37 31
Placenta weight (g) 1077 675 550 620 1077
C o t y l e d o n  w e i g h t  ( g ) 4 75 11 62 04 7
Total perfused (g) 113 157 86 112 113
Caesarean section N N N Y N
Gestation age (weeks + days) n.d. 41+3 41+0 39+1 39+4
S m o k e r NNNNN
Medicine N N Penicillin Innohep &
locoid one week
Citalopram
Details of donors and perfusion of five individual ex vivo placenta perfusions of PBDEs. The perfusions lasted four hours, except no. 3 for which 
leakage was detected after two hours.
n.d.: no data; afor the first two hours only.Frederiksen et al. Environmental Health 2010, 9:32
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formed by GC-MS using electron capture negative ioni-
sation (ECNI) on 60 m DB-5 and 15 m DB-1 columns.
The samples were analysed in batches of 24, which
included procedural blanks corresponding to perfusate/
plasma and placenta analytical methods, respectively, a
duplicate analysis of one of the placenta samples and
duplicate analyses of reference samples from the AMAP
ring test of persistent organic pollutants in human serum.
The limit of quantification (LOQ) was defined as the low-
est standard of the calibration curve deviating ≤ 20% from
the actual value if the compound was not detected in the
blank samples. Otherwise the LOQ was set to one cali-
bration level above the highest blank level. Thus LOQ is
dependent on instrumental sensitivity at the time of the
analysis and the blank level in each batch; typical LOQs
were 0.005 and 0.17 ng/ml perfusate or plasma for BDE-
47/-99 and BDE-209, respectively, or 0.001 and 0.06 ng/g
ww for placental tissue. However, BDE-209 concentra-
tions in the blank samples were not constant, but varied
between batches.
Total lipid content in placental tissue was determined
according to Smedes (1999) [28], while enzymatic lipid
determination of triglyceride and cholesterol was per-
formed on the plasma samples and total lipid was calcu-
lated as described by Covaci et al (2006) [29].
Statistical methods
Student's paired t-test was used for comparison of matri-
ces and compounds. The statistical analyses were carried
out using GraphPad Prism 5.0 (GraphPad Software Inc,
La Jolla, CA, USA).
Results and discussion
Perfusion experiments
In total, 89 samples of maternal and fetal perfusate, pla-
cental tissue and umbilical cord plasma from the five per-
fusions were analysed for PBDEs. The details of the five
placenta perfusions are given in Table 1. The cotyledon of
perfusion no. 3 was leaking towards the end of the perfu-
sion, therefore only data from the first 60 min of this per-
fusion have been used. All experiments meet the success
criteria on minimal leakage of fetal media (< 0.05 mL/
min) and a fetal/maternal ratio (FM-ratio) for antipyrine
transfer of at least 0.75 (Table 1). The oxygen transfer,
glucose consumption and lactate production were moni-
tored during the perfusion, and pH was kept in the physi-
ological range (data not shown) [23]. It is realised that the
final sampled volume of 42 ml removed from each reser-
voir may give a slightly different picture of transport
when looking at exact values as in figures 1 and 2. As the
exact same amount was removed from the fetal and
maternal reservoir at the same time-points and the
resulting concentration is unchanged by removal; the
large sample-volume demanded by the analysis protocol
for PBDE was allowed in these perfusions.
PBDE levels
The levels of BDE-47 and BDE-99 in the maternal per-
fusate declined rapidly in the beginning of the perfusion;
simultaneously, a significant increase in concentration
was observed in the fetal perfusate (pt(2-240), BDE47 = 0.0003
and pt(2-240), BDE99 = 0.0032) (Figure 1a and 1b). The initial
concentration (at t = 0) of the PBDEs in the maternal per-
fusate was above the expected level of 1 ng/mL that was
added, which indicates insufficient initial mixing of the
Figure 1 Placenta perfusion of BDE-47 and BDE-99. Concentration (ng/ml) and standard deviation of four hour placenta perfusions of a) BDE-47 
and b) BDE-99 after addition of 1 ng/mL of each congener to the maternal compartment at t = 0. (0-60 min: n = 5; 130-240 min: n = 4).
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medium. After 2 minutes the levels were below the
expected initial level. Neither BDE-47 nor BDE-99 was
detected above LOQ in any of the fetal or maternal per-
fusate samples taken prior to the experiment.
At the end of the perfusion the average maternal con-
centrations of BDE-47 and BDE-99 were 0.15 and 0.21
ng/mL, respectively. This is somewhat higher than the
median levels of BDE-47 found in recent studies of
maternal plasma and serum in Europe (0.003-0.02 ng/
mL), but within the range of recent adult median serum
levels in the United States (0.09-0.4 ng/mL), assuming a
lipid content of 0.8% [30]. This shows that the concentra-
tions used in this study are within the relevant range of
environmental exposure. The steady state concentrations
in the fetal circulation were 0.071 and 0.052 ng/mL for
BDE-47 and BDE-99, respectively, which was approxi-
mately 10 times higher than in the umbilical cord plasma
from this study (Table 2), but similar to median BDE-47
levels observed in US fetal serum of 0.03-0.08 ng/mL
when assuming a lipid content of 0.3% [31,32].
The mean concentrations of BDE-47 and BDE-99 found
in the non-perfused placental tissue were 0.84 and 0.38
ng/g lipid weight (lw), respectively (Table 2), and thereby
in line with those previously found in Denmark and Spain
[12,26]. The levels of BDE-47 were higher than those of
BDE-99, which is the general trend in mammalian sam-
ples. Compared with the non-perfused tissue the concen-
trations were significantly higher in the tissue
surrounding the cotyledon (p47 = 0.007; p99 = 0.013), and
the concentrations in the actually perfused cotyledons
were also significantly higher than in the surrounding
area (p47 = 0.007; p99 = 0.013) (Table 2). This shows that a
significant part of the amount of BDE-47 and BDE-99
added to the system accumulates in the placental tissue.
After the perfusion BDE-99 was present in higher con-
centration in the placental tissue than BDE-47, i.e. BDE-
99 accumulated in the tissue to a greater extent than
BDE-47.
Contamination during analysis and thereby fluctuating
blank levels are generally an obstacle in trace analysis of
Figure 2 Placenta perfusion of BDE-209. Concentration (ng/ml) and standard deviation of four hour placenta perfusions of BDE-209 after addition 
of 1 ng/mL to the maternal compartment at t = 0. (0-60 min: n = 5; 130-240 min: n = 4). The grey area indicates the concentration of the maximum 
pre-perfusion background level in the fetal circulation.
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BDE-209 [e.g. [33]]. Blank levels are caused by the omni-
presence of BDE-209, including computers and labora-
tory equipment, which can lead to high levels of BDE-209
in dust and indoor air, and contamination of samples and
equipment in spite of careful precautions. The measured
levels of BDE-209 in the non-perfused placental tissue
and fetal perfusate were not significantly different from
the relatively high blank levels (pplc = 0.3; pfet = 0.4), thus
we chose not to report BDE-209 concentrations for these
matrices (Figure 2). This critical and conservative
approach is in agreement with conclusions of interna-
tional PBDE intercalibration exercises [34] and the labo-
ratory's accreditation scheme. In future perfusion studies,
the use of isotope labelled BDE-209 could be considered
in order to eliminate the uncertainties resulting from lab-
oratory contamination.
In the maternal perfusate, a general decrease in BDE-
209 concentration could be observed (Figure 2), to a level
of 0.50 ng/mL after 4 hours of perfusion. This is roughly
one order of magnitude higher than actual observed
blood levels in recent studies from Denmark (~0.014 ng/
ml) and elsewhere (~0.009-0.15 ng/ml, assuming 0.8%
lipid content) [30,35]. In the present study, BDE-209
could not be determined in non-perfused placental tis-
sue, however, in a previous study of placental tissue col-
lected from the same hospital, a median level of 1.14 ng/g
lw was found [26]. If a similar level is assumed in the pres-
ent pre-perfusion samples, this will mean that during the
perfusion BDE-209 accumulates in both the perfused cot-
yledon and the surrounding tissue with concentrations
20- and 100-times the background, respectively. This
accumulation in placental tissue may explain why an
increase in fetal circulation cannot be observed.
Transport and kinetics of PBDEs
The ratio between the concentrations in the fetal and
maternal circulation (FM-ratio) during the perfusion was
calculated to evaluate the extent and kinetics of the trans-
fer (Figure 3). Steady-state was reached after approxi-
mately 190 min for both BDE-47 and BDE-99. For BDE-
47 and BDE-99 the FM-ratios were 0.47 and 0.25 at steady
state, respectively, thus indicating that the transfer of
these PBDEs was limited. The higher FM-ratio of BDE-47
showed that it was transported across the placenta to a
greater extent than BDE-99 (p = 0.0006). These results
are in line with previous findings of decreasing placental
transfer with increasing degree of bromination in paired
maternal and umbilical cord blood [35,36]. Increasing
affinity with tissue with increasing logKOW  is a likely
explanation for the decreasing placental transfer. Other
compound characteristics that could affect the transport
are molecular size and resulting steric hindrance [35,37]
Table 2: PBDE levels in placental tissue, umbilical cord blood as well as fetal and maternal perfusate.
BDE-47 BDE-99 BDE-209 Lipid content (%)
Cotyledon (perfused tissue) (ng/g lw) 47.9
(32.0-61.0)
73.0
(38.6-98.5)
107.8
(64.2-159.5)
1.14
(1.10-1.21)
Surrounding placental tissue (ng/g lw) 16.8
(10.7-21.04)
22.4
(16.2-27.5)
22.2
(16.3-31.8)
1.14
(1.03-1.22)
Non-perfused placental tissue (ng/g lw) 0.84
(0.57-1.16)
0.38
(< 0.11-0.75)
< LOQ 1.10
(0.95-1.34)
Umbilical cord plasma
(ng/g lw)
2.37
(0.41-3.77)
1.78
(1.09-3.09)
< LOQ 0.33
(0.29-0.40)
Umbilical cord plasma
(ng/g ww)
0.0078
(0.0047-0.0108)
0.0058
(0.0034-0.0089)
< LOQ 0.33
(0.29-0.40)
Fetal perfusate,
t = 240 min (ng/ml)
0.071
(0.050-0.094)
0.052
(0.030-0.076)
< LOQ n.a.
Maternal perfusate, t = 240 min (ng/ml) 0.15
(0.12-0.18)
0.21
(0.13-0.31)
0.50a
(0.46-0.58)
n.a.
Mean and range of PBDE levels in placental tissue, umbilical cord plasma as well as in maternal and fetal perfusate at steady state. Lipid weight 
basis: ng/g lw, wet weight basis: ng/g ww. (n = 4).
LOQ: Limit of quantification. n.a.: not applicable; aone high outlier was removed.Frederiksen et al. Environmental Health 2010, 9:32
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or possibly differences in affinity for carrier proteins of
e.g. albumin which may control the transport of the larger
congeners [38].
T h e  r a p i d  d e c r e a s e  i n  m a t e r n a l  l e v e l s  i n d i c a t e s  t h a t
BDE-209 is either transferred across the placenta or accu-
mulated in the tissue. While BDE-209 has been detected
quite frequently in adult blood samples [39-41] there are
only few studies on BDE-209 in cord blood. Of these,
some have found BDE-209 above the LOQ [12,22,42],
mostly at low detection frequencies, while others have
not [31,35,43]. Thus, in spite of the many samples below
LOQ in several studies, results from the literature indi-
cate that some transport of BDE-209 across the placenta
occurs. In addition, it may be relevant to consider debro-
mination products, which are both more toxic and trans-
portable than the parent compound itself, when
addressing in utero toxicity of BDE-209. However, the
metabolic pathway of BDE-209 in humans is poorly
understood. Furthermore, BDE-209 can be degraded to
lower brominated compounds, leading to a potentially
continued exposure to these more bioaccumulative and
toxic compounds.
The rate of the transfer can be studied by the indicative
permeability coefficient (IPC), which gives a quantitative
indication of the permeability of the placenta for a given
compound. IPC can be estimated from the slope of the
initial linear section of the FM-ratio graph [44]. For BDE-
47 and BDE-99, the initial linear slope covered the period
from 0 to 60 minutes in Figure 3; from this, the IPC was
calculated to be 0.26 h-1 and 0.10 h-1 for BDE-47 and
BDE-99, respectively. This indicates a higher transfer rate
for BDE-47 compared to BDE-99 (p = 0.014). For com-
parison, the IPC for the control substance antipyrine, the
pesticide glyphosate, the alkaloid caffeine and the preser-
vative benzoic acid were 0.94 h-1, 0.11 h-1, 1.03 h-1 and 0.6
h-1, respectively, when perfused in the same human pla-
centa model [44], and the IPC of the lipophilic substance
benzo(a)pyrene was 0.08 h-1 [45]. This places BDE-99
close to glyphosate and BDE-47 between glyphosate and
benzoic acid with regards to the rate of the placental
Figure 3 Fetal-maternal ratios of BDE-47 and BDE-99. Mean and standard deviation of fetal/maternal concentration ratios (FM-ratios) for BDE-47 
and BDE-99 during four hour placenta perfusions. (0-60 min: n = 5; 130-240 min: n = 4).
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transport in spite of the very different properties, includ-
ing, for example, aqueous solubility.
Mass balances
A mass balance was calculated for each congener to eval-
uate the partitioning between the compartments at
steady state using the weight or volume and the concen-
trations in the different compartments. The recoveries of
the added compounds in the different compartments are
shown in Figure 4. For BDE-47 and BDE-99, only 7.8%
and 10.9%, respectively, were still in the maternal circula-
tion at the end of the perfusion. Apart from the quantity
which was removed by sampling or adsorbed to the sys-
tem, the largest fraction was found in the perfused cotyle-
don of the placenta for both BDE-47 and BDE-99, though
the amount in the surrounding tissue was almost equal
but with a lower absolute concentration (Table 2). Thus,
the majority of BDE-47 and BDE-99 was accumulated
and recovered in the placental tissue. For BDE-47, 35% of
the added amount was unaccounted for, which is in
agreement with the initial system adsorption test and
could reflect, for example, binding to blood cells that
were removed by centrifugation prior to sample analysis.
For BDE-99, 23% of the added amount was unaccounted
for by tissue and media content, which is also very close
to the loss observed in the system adsorption test.
No mass loss of BDE-209 was observed in the system
adsorption test; however, this could be masked by the
background contamination with BDE-209. The BDE-209
fractions reported (Figure 4) are indicative values where
high outliers have been removed; the system adsorption
was negative. This might indicate that the system has
contributed slightly to the total amount of BDE-209 in
the system, but could also be a result of the higher mea-
surement uncertainty for BDE-209. As for BDE-47 and
BDE-99, the majority of the BDE-209 added to the perfu-
sion system accumulated in the placental tissue. However,
a higher percentage than those of BDE-47 and BDE-99
remained in the maternal circulation after four hours of
perfusion.
The mass balances do not include metabolites of the
PBDEs such as hydroxyl- and methoxy-metabolites,
though it is possible that differences in the metabolisation
rates may account for some of the observed differences
Figure 4 Mass balance of BDE-47, BDE-99 and BDE-209 in the placenta perfusion system. Fractions of originally added PBDE amounts in per-
fusate, placental tissue and removed by sampling. The amount unaccounted for is given as system adsorption. The numbers given for BDE-209 are 
indicative values (marked with *) due to possible contributions from the surroundings and higher measurement uncertainty.
 System adsorption 
BDE-47:  34.7% 
BDE-99:  23.0% 
BDE-209*: -8% 
Surrounding 
 placental tissue 
BDE-47:  16.6% 
BDE-99:  19.8% 
BDE-209*: 19% 
Maternal circulation 
BDE-47:  7.8% 
BDE-99:  10.9% 
BDE-209*: 27% 
Fetal circulation 
BDE-47:  4.3% 
BDE-99:  3.0% 
BDE-209*: 0% 
Cotyledon 
BDE-47:  17.5% 
BDE-99:  20.3% 
BDE-209*: 24% 
Sampling 
BDE-47:  19.1%  
BDE-99:  23.0% 
BDE-209*: 38% Frederiksen et al. Environmental Health 2010, 9:32
http://www.ehjournal.net/content/9/1/32
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between the compounds. However, given the short time
period of the study and the fact that the levels of PBDE
metabolites generally are less than 10% of the parent
compound in human plasma/serum [46,47] the metabo-
lites would probably be difficult to detect with the current
study setup.
Benefits and limitations of the human placenta perfusion 
system
Placental passage studied in a human ex vivo placenta
perfusion system provides human data non-invasively
and with no major ethical concerns as the tissue is usually
discarded after the birth. The setup is controlled and sev-
eral compounds can be studied at the same time and can
include kinetics, which is not possible to study in vivo.
H o w e v e r ,  t h e  m e t h o d  a l s o  h a s  s o m e  l i m i t a t i o n s ,  f o r
example, the necessity to exchange the blood with buffer
solutions and a time limit of about six hours available for
the transfer study [23]. To increase the solubility of the
PBDEs in the buffer solutions, we added human serum
albumin at physiological levels, and even though the
study period is relatively short, the current results indi-
cate that steady-state was obtained for BDE-47 and BDE-
99 during the perfusion. Placental thickness and number
of cell layers to pass from the maternal to the fetal circu-
lation decrease towards the end of the pregnancy. Thus,
the term placenta is considered more sensitive to xenobi-
otics than the placenta at earlier stages of pregnancy [48].
Conclusion
To our knowledge this is the first placenta perfusion
study of PBDEs. The observed transport of BDE-47 and
BDE-99 across the placenta shows in utero exposure to
PBDEs. The transport of BDE-47 occurred faster and
more extensively than for BDE-99. In conclusions, our
study clearly demonstrates fetal exposure to PBDEs, and
t h i s  m u s t  b e  c o n s i d e r e d  i n  r i s k  a s s e s s m e n t s  o f  P B D E
exposure of women of child-bearing age.
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